Tags

Type your tag names separated by a space and hit enter

Therapeutic Outcomes of Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Severe Aplastic Anemia: A Multicenter Study.
Transplantation. 2018 10; 102(10):1724-1731.T

Abstract

BACKGROUND

Haploidentical donor (HID) allogeneic hematopoietic stem cell transplantation (HSCT) is an alternative curative treatment for patients with severe aplastic anemia (SAA) who do not have suitable matched related donors (MRD). The aim of this study was to compare the therapeutic outcomes of HID-HSCT with those of MRD-HSCT for SAA.

METHODS

A total of 235 SAA patients who underwent HID-HSCT (116) or MRD-HSCT (119) at 11 transplantation centers from January 2007 to January 2016 were included. Complications and survival outcomes were evaluated and compared between the 2 groups.

RESULTS

The HID group had a lower incidence of secondary graft failure but higher incidences of acute graft-versus-host disease (aGVHD) and chronic GVHD (cGVHD). However, the incidence of severe aGVHD (grades III-IV), poor graft function, and infections was comparable between groups. Patients in the HID group had a significantly lower survival and overall survival rates than those in the MRD group. The estimated 3-year survival rates for the MRD and HID groups were 82.82% and 75.00%, respectively. Ferritin levels, graft failure, poor graft function, severe aGVHD, and infections were the significant risk factors for survival.

CONCLUSIONS

The overall survival rate is acceptable for patients who underwent HID-HSCT, making it a feasible treatment choice for SAA patients.

Authors+Show Affiliations

Guangzhou General Hospital of Guangzhou Military Command, Guangzhou, China.Southern Medical University, Guangzhou, China.Guangzhou General Hospital of Guangzhou Military Command, Guangzhou, China.The First Affiliated Hospital to Chinese PLA General Hospital, Beijing, China.Guangzhou First People's Hospital, Guangzhou, China.The First Affiliated Hospital of Zhongshan University, Guangzhou, China.Nanfang Hospital, Southern Medical University, Guangzhou, China.Nanfang Hospital, Southern Medical University, Guangzhou, China.Sun Yat-sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.The First Affiliated Hospital of Guangxi medical university, NanNing, China.Zhujiang Hospital of Sourthern Medical University, Guangzhou, China.Third Hospital of Sun Yat-Sen University, Guangzhou, China.Guangdong General Hospital, Guangzhou, China. Shenzhen Second People Hospital, Shenzhen, China.Guangdong General Hospital, Guangzhou, China.Guangzhou General Hospital of Guangzhou Military Command, Guangzhou, China.Guangzhou General Hospital of Guangzhou Military Command, Guangzhou, China.Guangzhou General Hospital of Guangzhou Military Command, Guangzhou, China.Guangzhou General Hospital of Guangzhou Military Command, Guangzhou, China.Guangzhou General Hospital of Guangzhou Military Command, Guangzhou, China.Southern Medical University, Guangzhou, China.Southern Medical University, Guangzhou, China.Southern Medical University, Guangzhou, China. Stem Cell Translational Medicine Center, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.

Pub Type(s)

Comparative Study
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

29677078

Citation

Li, Yonghua, et al. "Therapeutic Outcomes of Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Severe Aplastic Anemia: a Multicenter Study." Transplantation, vol. 102, no. 10, 2018, pp. 1724-1731.
Li Y, Duan F, Xiao H, et al. Therapeutic Outcomes of Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Severe Aplastic Anemia: A Multicenter Study. Transplantation. 2018;102(10):1724-1731.
Li, Y., Duan, F., Xiao, H., Wu, X., Wang, S., Xu, D., Liu, Q., Fan, Z., Nie, D., Lai, Y., Wu, B., Lin, D., Du, X., Weng, J., Jiang, Z., Pang, Y., Ouyang, L., Liu, Z., Zhang, L., ... Xiao, Y. (2018). Therapeutic Outcomes of Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Severe Aplastic Anemia: A Multicenter Study. Transplantation, 102(10), 1724-1731. https://doi.org/10.1097/TP.0000000000002200
Li Y, et al. Therapeutic Outcomes of Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Severe Aplastic Anemia: a Multicenter Study. Transplantation. 2018;102(10):1724-1731. PubMed PMID: 29677078.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Therapeutic Outcomes of Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Severe Aplastic Anemia: A Multicenter Study. AU - Li,Yonghua, AU - Duan,Fengqi, AU - Xiao,Haowen, AU - Wu,Xiaoxiong, AU - Wang,Shunqing, AU - Xu,Duorong, AU - Liu,Qifa, AU - Fan,Zhiping, AU - Nie,Danian, AU - Lai,Yongrong, AU - Wu,Bingyi, AU - Lin,Dongjun, AU - Du,Xin, AU - Weng,Jianyu, AU - Jiang,Zujun, AU - Pang,Yan, AU - Ouyang,Ling, AU - Liu,Zenghui, AU - Zhang,Leqin, AU - Han,Na, AU - Chen,Lixuan, AU - Xiao,Yang, PY - 2018/4/21/pubmed PY - 2019/4/16/medline PY - 2018/4/21/entrez SP - 1724 EP - 1731 JF - Transplantation JO - Transplantation VL - 102 IS - 10 N2 - BACKGROUND: Haploidentical donor (HID) allogeneic hematopoietic stem cell transplantation (HSCT) is an alternative curative treatment for patients with severe aplastic anemia (SAA) who do not have suitable matched related donors (MRD). The aim of this study was to compare the therapeutic outcomes of HID-HSCT with those of MRD-HSCT for SAA. METHODS: A total of 235 SAA patients who underwent HID-HSCT (116) or MRD-HSCT (119) at 11 transplantation centers from January 2007 to January 2016 were included. Complications and survival outcomes were evaluated and compared between the 2 groups. RESULTS: The HID group had a lower incidence of secondary graft failure but higher incidences of acute graft-versus-host disease (aGVHD) and chronic GVHD (cGVHD). However, the incidence of severe aGVHD (grades III-IV), poor graft function, and infections was comparable between groups. Patients in the HID group had a significantly lower survival and overall survival rates than those in the MRD group. The estimated 3-year survival rates for the MRD and HID groups were 82.82% and 75.00%, respectively. Ferritin levels, graft failure, poor graft function, severe aGVHD, and infections were the significant risk factors for survival. CONCLUSIONS: The overall survival rate is acceptable for patients who underwent HID-HSCT, making it a feasible treatment choice for SAA patients. SN - 1534-6080 UR - https://www.unboundmedicine.com/medline/citation/29677078/Therapeutic_Outcomes_of_Haploidentical_Allogeneic_Hematopoietic_Stem_Cell_Transplantation_in_Patients_With_Severe_Aplastic_Anemia:_A_Multicenter_Study_ L2 - http://dx.doi.org/10.1097/TP.0000000000002200 DB - PRIME DP - Unbound Medicine ER -